NCT07818135 Comparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLC
| NCT ID | NCT07818135 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Carlos Déniz |
| Condition | Non-Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-01-15 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study compares two established robotic surgical approaches for removing lung tumors in adults with non-small cell lung cancer: biportal robotic-assisted thoracic surgery (biRATS) and multiportal robotic-assisted thoracic surgery (multiRATS). Participants are assigned at random to one of the two approaches. The study will compare surgical safety, recovery after surgery, pain, length of hospital stay, quality of life, and other clinical outcomes during 12 months of follow-up.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older, of any sex. * Non-small cell lung cancer considered clinically resectable, confirmed preoperatively or during surgery. * Candidate for pulmonary resection by robotic thoracic surgery. * Written informed consent. Exclusion Criteria: * Declines participation or cannot provide written informed consent. * Thoracic anatomical abnormalities that preclude or materially affect robotic surgery. * Active thoracic infection. * Surgery not performed by a participating surgeon with comparable experience in biRATS and multiRATS.
Contact & Investigator
Carlos Déniz Armengol, MD, PhD
PRINCIPAL INVESTIGATOR
Hospital Universitari de Bellvitge
Frequently Asked Questions
Who can join the NCT07818135 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07818135 currently recruiting?
Yes, NCT07818135 is actively recruiting participants. Contact the research team at cjdeniz@bellvitgehospital.cat for enrollment information.
Where is the NCT07818135 trial being conducted?
This trial is being conducted at L'Hospitalet de Llobregat, Spain.
Who is sponsoring the NCT07818135 clinical trial?
NCT07818135 is sponsored by Carlos Déniz. The principal investigator is Carlos Déniz Armengol, MD, PhD at Hospital Universitari de Bellvitge. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.